Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) fell approximately 3.7% after the company reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014 wider than the Zacks Consensus Estimate of loss of 11 cents.
July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) and marketing partner Eisai (OTCPK:ESALY). Belviq had its initial launch in June of ... Needless to say, Arena stock suffered because sales ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Friday. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.